Q3 2017

Latest Quarterly Results
Ended March 31, 2017

$714,889

Research and development YTD

$1,449,080

Net cash used in operations YTD

Company Profile

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

Frequently Asked Questions

Answers to commonly asked questions

View FAQ

IR Contact Information

Transfer Agent

Corporate Stock Transfer Inc.
3200 Cherry Creek South Drive
Suite 430
Denver, CO 80209
T: 303-282-4800
dbell@corporatestock.com
www.corporatestock.com